TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01678131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaniprevir 600 mg
Description: Vaniprevir capsules, were administered orally, twice per day (BID) to achieve a final daily dose of 600 mg on Days 1 through 6; and a single dose of 600 mg, orally, on Day 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaniprevir 600 mg
Description: Vaniprevir capsules, were administered orally, twice per day (BID) to achieve a final daily dose of 600 mg on Days 1 through 6; and a single dose of 600 mg, orally, on Day 7.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peg-IFN alfa-2b
Description: Peg-IFN alfa-2b was administered at 1.5 µg/kg per week by subcutaneous injections on Days 1, 8, 15 and 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peg-IFN alfa-2b
Description: Peg-IFN alfa-2b was administered at 1.5 µg/kg per week by subcutaneous injections on Days 1, 8, 15 and 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin capsules were administered on Days 1-21, orally, twice daily for a total daily dose of 600 - 1400 mg, depending on the participant's weight

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin capsules were administered on Days 1-21, orally, twice daily for a total daily dose of 600 - 1400 mg, depending on the participant's weight

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver samples from FNA
Description: Liver samples were collected from Day 7 up to Day 10 by FNA at 3 of 5 specified postdose timepoints.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver samples from FNA
Description: Liver samples were collected from Day 7 up to Day 10 by FNA at 3 of 5 specified postdose timepoints.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver samples from FNA
Description: Liver samples were collected from Day 7 up to Day 10 by FNA at 3 of 5 specified postdose timepoints.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaniprevir 300 mg
Description: Vaniprevir capsules were administered orally, twice per day to achieve a final daily dose of 300 mg on Days 1 through 6; and a single dose of 300 mg, orally, on Day 7.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver samples from CNB
Description: Liver samples were collected from Day 8 up to Day 10 by CNB at 1 of 3 specified postdose timepoints.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver samples from CNB
Description: Liver samples were collected from Day 8 up to Day 10 by CNB at 1 of 3 specified postdose timepoints.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver samples from CNB
Description: Liver samples were collected from Day 8 up to Day 10 by CNB at 1 of 3 specified postdose timepoints.
Study: NCT01987739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT03980925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Subjects will receive Nivolumab 360 mg every 3 weeks (Q3W) first day of each cycle plus Carboplatin area under the curve (AUC5) Q3W first day of each cycle plus Etoposide 100 day 1-3 of each cycle up to 6 cycles of combined therapy (Induction Phase).~At the time of completion of 6 cycles of chemotherapy and nivolumab, participants who have not experienced disease progression will continue to receive nivolumab at a dose of 480 mg as 30 minute infusion every 4 weeks for up to 2 years (24 months) (maintenance phase).~Cycles are defined by 4 weeks or 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Subjects will receive Nivolumab 360 mg every 3 weeks (Q3W) first day of each cycle plus Carboplatin AUC5 Q3W first day of each cycle plus Etoposide 100 day 1-3 of each cycle up to 6 cycles of combined therapy (Induction Phase).~At the time of completion of 6 cycles of chemotherapy and nivolumab, participants who have not experienced disease progression will continue to receive nivolumab at a dose of 480 mg as 30 minute infusion every 4 weeks for up to 2 years (24 months) (maintenance phase).~Cycles are defined by 4 weeks or 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Subjects will receive Nivolumab 360 mg every 3 weeks (Q3W) first day of each cycle plus Carboplatin AUC5 Q3W first day of each cycle plus Etoposide 100 day 1-3 of each cycle up to 6 cycles of combined therapy (Induction Phase).~At the time of completion of 6 cycles of chemotherapy and nivolumab, participants who have not experienced disease progression will continue to receive nivolumab at a dose of 480 mg as 30 minute infusion every 4 weeks for up to 2 years (24 months) (maintenance phase).~Cycles are defined by 4 weeks or 28 days.
Study: NCT01987739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT01636999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50% Nitrous Oxide/50% Oxygen
Description: The gas mixture is provided via the Sedara portable gas delivery system. This system is equipped with a non-rebreather mask which the patient holds over their mouth and nose. The delivery of the gas is only triggered by the patient's spontaneous breath. The gas machine will be provided to the patient to use as much as they like during the 60 minutes data collection period. The only dose which the machine allows to be administered is 50% Nitrous Oxide/50% oxygen.
Study: NCT04552743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGTA-145
Description: A chemokine receptor type 2 (CXCR2) agonist protein, administered via intravenous (IV) infusion over 3 to 10 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: An azamacrocycle CXCR4 chemokine receptor antagonist, administered at 0.24 mg/kg subcutaneously, reduced to 0.16 mg/kg in patients with renal dysfunction (per package insert).
Study: NCT02801539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RMT therapy using modified RMT device
Description: The exercises provided by the RMT device is intended to strengthen breathing muscles.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-RMT therapy using modified RMT device
Description: The exercises provided by the Sham-RMT modified device is not intended to strengthen breathing muscles.
Study: NCT04204200

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: liposomal vitamin C
Description: The intake of liposomal vitamin C at 500 mg, in the morning and evening, one week before surgery, one during the day of surgery and lastly, during the first 21 post operation days.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: standard vitamin C
Description: The intake of traditional vitamin C with a daily intake of 500 mg in the morning and evening for 28 days (starting 7 days before the operative procedure, on the day of the surgery and ending twenty-one days after surgery).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The intake placebo was taken daily in the morning and the evening for 28 days (7 days before surgery, on the day of surgery and twenty-one days after the surgical procedure).
Study: NCT03152084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: The study consists of a 2-week, open label, dapagliflozin (10mg) treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: The study consists of a 2-week, open label, dapagliflozin (10mg) treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: The study consists of a 2-week, open label, dapagliflozin (10mg) treatment period.
Study: NCT02522858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: To evaluate the effectiveness of atropine on prevention bradycardia,atropine 0.01\~0.03mg/kg up to 0.5mg would be injected intravenously just before starting loading dose of dexmedetomidine in group A.~During operation, heart rate decreasing 30% from initial heart rate or under 40/min would be regarded as bradycardia needing treatment, and atropine 0.5mg will be injected intravenously. This intervention would be applied to both group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine is a highly selective a2 adrenergic receptor antagonist used as sedative agent. After confirming the fixation level of spinal anesthesia, the loading dose(0.6ug/kg) of dexmedetomidine which is diluted with normal saline as 4ug/mL would be started for 10 minutes.Maintenance dose(0.25ug/kg/hr) would be continued after loading dose.
Study: NCT02610335

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group (C)
Description: * kyphosis reeducation on Huber platform during 2 weeks,~* patient education : on physiopathology of the lumbar spinal stenosis and treatments as well as healthy lifestyle and prevention (plans of anatomy, plastic column, slides of medical imaging),~* flexibility exercises, stretching exercises and abdominal muscles exercises : to continue at home (the exercises will be reported on a book that will be given to the patient),~* exercises on cycle ergometer or walking on treadmill : to continue at home.

Intervention type: OTHER
Group type: OTHER
Intervention: Test group
Description: * spinal mobility reeducation on Huber platform during 2 weeks,~* patient education : on physiopathology of the lumbar spinal stenosis and treatments as well as healthy lifestyle and prevention (plans of anatomy, plastic column, slides of medical imaging),~* flexibility exercises and mobilization exercises : to continue at home (the exercises will be reported on a book that will be given to the patient),~* exercises on cycle ergometer or walking on treadmill : to continue at home.
Study: NCT04136704

Intervention type: PROCEDURE
Intervention: Sleeve gastrectomy
Description: Laparoscopic sleeve gastrectomy

Intervention type: PROCEDURE
Intervention: Sleeve gastrectomy
Description: Laparoscopic sleeve gastrectomy
Study: NCT04499300

Intervention type: OTHER
Intervention: Data collection from medical files
Description: Data collection from medical files
Study: NCT02522858

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine is a highly selective a2 adrenergic receptor antagonist used as sedative agent. After confirming the fixation level of spinal anesthesia, the loading dose(0.6ug/kg) of dexmedetomidine which is diluted with normal saline as 4ug/mL would be started for 10 minutes.Maintenance dose(0.25ug/kg/hr) would be continued after loading dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: Systolic blood pressure decreasing 30% from basal blood pressure or under 90 mm Hg would be regarded as hypotension needing treatment, and ephedrine 5mg will be injected intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ephedrine
Description: Systolic blood pressure decreasing 30% from basal blood pressure or under 90 mm Hg would be regarded as hypotension needing treatment, and ephedrine 5mg will be injected intravenously.
Study: NCT03078088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tham
Description: alkalinizer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo
Study: NCT00554008

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic appendectomy
Description: appendix removal via scope

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open appendectomy
Description: open operation for removal of appendix
Study: NCT00982930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation powder
Description: Tobramycin inhalation powder, 112 mg (4 capsules of 28 mg), inhalation capsules, b.i.d.
Study: NCT02859402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: intravenous, 3.2 mg/kg + 5% DW (the diluent quantity should be 10 times the volume of Busulfan, so that the final concentration of busulfan becomes approximately 0.5 mg/mL), once daily for 3 hours for 3 days (days -7 to -5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: intravenous, 30 mg/m2 + 5% DW 100㎖, over 1 hour once daily for 6 days (days -8 to -3)
Study: NCT01899313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT- based SMS text messaging intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT group therapy

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: CBT group therapy
Study: NCT02513108

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: same day discharge
Description: same day discharge after PCI for stable CAD
Study: NCT02252419

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Paracetamol will be administered.
Study: NCT03252080

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: short-term intensive education
Description: The patients of both groups are given the education classes once a week in the first month (total 4 times), 5 hours per class. The education classes are taught by a dedicated team of diabetes specialist doctors and nurses, with the contents including a basic understanding of diabetes, diabetic diet, exercise, drug treatments and blood glucose monitoring.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: short-term intensive education
Description: The patients of both groups are given the education classes once a week in the first month (total 4 times), 5 hours per class. The education classes are taught by a dedicated team of diabetes specialist doctors and nurses, with the contents including a basic understanding of diabetes, diabetic diet, exercise, drug treatments and blood glucose monitoring.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Holistic management
Description: The specialist nurses talk individually with the patients for 10-15 min per week. The nurses ask the patients about their results of self-blood glucose monitoring, help them find the reasons of poor blood glucose control as well as answer the patient's questions.
Study: NCT02582138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (MCI)
Description: The multicomponent intervention will include physical activity (PA), nutrition and information and communications technology (ICT). The PA will be of moderate intensity and will include aerobic, strength, flexibility, and balance training. Walking will be the primary mode of PA .~The nutritional intervention will combine individual nutritional assessment and personalised dietary recommendations to achieve:~* a daily total energy intake of 25-30 kcal/kg body weight;~* an average protein daily intake between 1.0 and 1.2 g/Kg/body weight.~The ICT component will involve the use of an ad hoc technological device to record actimetry data to support the elaboration of a personalised training programme.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Aging Lifestyle Education (HALE)
Description: The healthy aging lifestyle education programme will be based on a workshop series. Participants will receive information on a variety of topics of relevance to older adults (e.g., recommended preventive services and screenings at different ages). The programme will also include a short instructor-led programme (5-10 minutes) of upper extremity stretching exercises or some relaxation techniques that will be performed at the end of each workshop.
Study: NCT01665703

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG PET/MR
Description: Patients will be asked to undergo a voluntary gadolinium enhanced MRI with simultaneous acquisition of FDG-PET uptake within 4 weeks prior to surgery.
Study: NCT03256825

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Rapid diagnostics alone
Description: Urine samples present at the laboratory at opening on weekdays will be screened using urine flow cytometry and microscopy of centrifuged gram stained urine. Samples found positive for significant mono microbial bacteriuria will be investigated further by using direct automated phenotypic identification and antimicrobial susceptibility determination.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Rapid diagnostics alone
Description: Urine samples present at the laboratory at opening on weekdays will be screened using urine flow cytometry and microscopy of centrifuged gram stained urine. Samples found positive for significant mono microbial bacteriuria will be investigated further by using direct automated phenotypic identification and antimicrobial susceptibility determination.

Intervention type: OTHER
Group type: OTHER
Intervention: Real-time antimicrobial stewardship decision support
Description: A clinical microbiologist will be give RADS by phone to a designated clinician with the aim of:~1. Switch to active treatment if non-working empirical treatment~2. De-escalate broad spectrum empiric treatment when feasible~3. Promote early intravenous to per oral switch~4. Shorten treatment duration
Study: NCT02716948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo stereotactic radiosurgery
Study: NCT03968757

Intervention type: DEVICE
Intervention: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)
Description: Device for creation of anastomoses during laparoscopic RYGB surgery manufactured by Ezisurg Medical.
Study: NCT02833688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: dexmedetomidine 2mg is diluted in 0.9% sodium chloride with the concentration of 4 ug ml-1 is administered with an loading dose of 0.5ug kg-1 of 10 min, and maintained with infusion rate of 0.5 ug kg-1 h-1. The infusion is ceased after the resection of the hepatic issues.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride
Description: 0.9% sodium chloride is administered with an loading dose of 0.5ug kg-1 of 10 min, and maintained with infusion rate of 0.5 ug kg-1 h-1. The infusion is ceased after the resection of the hepatic issues.
Study: NCT02233933

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hemospray
Description: hemospray is used after argon coagulation to stop bleeding

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hemospray
Description: hemospray is used after argon coagulation to stop bleeding
Study: NCT04242433

Intervention type: DRUG
Intervention: Direct Acting Antivirals
Description: All subjects with viremic chronic hepatitis C will be given DAAs based on the MMPHCRF Treatment algorithm. Patients will be assessed for cirrhosis, prior treatment exposure, high risk groups like dialysis patients, HIV-HCV coinfection, etc. Accordingly treatment will be provided at any of the 25 peripheral centres or at the apex nodal treatment centre (PGIMER) of the MMPHCRF.~Baseline and post treatment RAS samples will be collected with consent.
Study: NCT03652974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium valproate with Clozapine
Description: sodium valproate may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: modified electroconvulsive therapy(MECT) with Clozapine
Description: modified electroconvulsive therapy(MECT) may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amisulpride with Clozapine
Description: amisulpride may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo with Clozapine
Description: placebo may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
Study: NCT01638247

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 25 mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen and GnRH analogue
Description: 25 mg Tamoxifen daily and GnRH analogue:~* Goserelin (10.8 mg s.c. after randomisation and after three months) or~* Leuprorelin (11.25 mg s.c. after randomisation and after three months).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane and GnRH analogue
Description: 25 mg Exemestane daily and GnRH analogue:~* Goserelin (10.8 mg s.c. after randomisation and after three months) or~* Leuprorelin (11.25 mg s.c. after randomisation and after three months).
Study: NCT02170025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY63-2521)
Description: Participants received 0.5 mg BAY63-2521 three times daily (tid) for 14 days. The dose would be increased to 1 mg BAY63-2521 for an additional 14 days, if this was considered safe and tolerable on the basis of the available data for a given patient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants received matching placebo tid.
Study: NCT03637244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Support Aid and PrEP for Black Canadians
Description: Ottawa Decision Support Framework Adaptation.Investigators will use the inputs from the qualitative findings, CDC public health guidance and the tenofovir + emtricitabine product monograph to tailor the ODSF for use in the C5TM PrEP decision support web-app.
Study: NCT01489189

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prompt Panretinal Photocoagulation
Description: Panretinal photocoagulation alone at baseline (full session completed within 56 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5-mg Ranibizumab
Description: Intravitreal injection of 0.5 mg ranibizumab (Lucentis™) at baseline and up to every 4 weeks using defined retreatment criteria.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deferred panretinal photocoagulation
Description: PRP is deferred until failure/futility criteria for intravitreal injection are met.